Ann: PromarkerD Update, page-2

Predictive diagnostic test for diabetic kidney disease:
PromarkerD update
Proteomics International Laboratories Ltd (ASX: PIQ) (PILL), the leader in predictive diagnostics for
diabetic kidney disease, presents a comprehensive update on commercialisation progress for its
PromarkerD test.
 PromarkerD rated the world's leading diagnostic test for diabetic kidney disease by global
market research firm Frost & Sullivan
 First licensing income received
 Key patents secured and extended
 Clinical laboratory prototype manufacture on target for mid-2017
 First commercial sales are targeted for the end of 2017
 Validation study completed - announcement of results pending publication of the prior
predictive development study
 Development study shows PromarkerD correctly predicts 95% of otherwise healthy diabetics
who will develop chronic kidney disease
 Discussions continue with prospective diagnostic companies in the USA, China, Europe,
Australia and Japan to secure licences for the commercialisation of PromarkerD

Only wondering: If first sales are end of 2017, where did the first income come from?